Antares Pharma Inc

Antares Pharma Inc

ATRS - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$950.88M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Antares Pharma IncAntares Pharma Inc20.7-23%5.60.1
$5.98

Current Fair Value

6.9% upside

Undervalued by 6.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$950.88 Million
Enterprise Value$908.06 Million
Earnings per Share$0.27
Beta1.15
Outstanding Shares170,104,000

Return

Return on Equity22.86%ROE
Return on Assets15.71%
Return on Invested Capital9.57%

Valuation & Multiples

P/E Ratio20.7P/E Ratio
PEG-12.84PEG
Price to Sales5.59Price to Sales
Price to Book Ratio5.59Price to Book Ratio
Enterprise Value to Revenue-0.23
Enterprise Value to EBIT-2.24
Enterprise Value to Net Income22
Total Debt to Enterprise-0.45
Debt to Equity0.11Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Antares Pharma Inc

CEO: Robert Apple

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Com...

Antares Pharma Insider Information FAQ

In the latest 13F quarter on Stockcircle, 3 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.